Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?


OverviewForecastFinancialsChartTranscripts

Allogene Therapeutics Ownership Summary


Allogene Therapeutics is owned by 131.06% institutional investors, 11.03% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.55% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 5.10% of its assets in Allogene Therapeutics shares.

ALLO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAllogene Therapeutics131.06%11.03%-42.10%
SectorHealthcare Stocks 50.59%12.40%37.01%
IndustryBiotech Stocks 49.10%12.14%38.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de30.15M12.55%$62.71M
Blackrock16.45M9.72%$38.32M
Frazier life sciences management22.45M9.34%$46.69M
Pfizer22.03M9.17%$46.93M
State street19.03M7.92%$39.57M
Tpg gp a18.72M7.79%$38.93M
Sio capital management13.32M5.54%$27.71M
Primecap management co/ca/13.12M5.46%$27.30M
Vanguard capital management12.17M5.06%$25.31M
Fmr12.01M5.00%$24.98M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pfizer22.03M27.55%$46.93M
Vida ventures advisors1.80M7.59%$2.23M
Sio capital management13.32M4.59%$27.71M
Wildcat capital management2.92M2.66%$6.08M
Patient square capital lp5.05M1.63%$10.50M
Frazier life sciences management22.45M1.02%$46.69M
Dafna capital management2.00M0.79%$4.16M
Tpg gp a18.72M0.78%$38.93M
Harold davidson & associates281.52K0.25%$585.57K
Boxer capital management1.50M0.23%$3.12M

Top Buyers

HolderShares% AssetsChange
Frazier life sciences management22.45M1.02%18.65M
Sio capital management13.32M4.59%13.32M
Blackrock funding, inc. /de30.15M0.00%11.06M
Fmr12.01M0.00%10.42M
State street19.03M0.00%10.37M

Top Sellers

HolderShares% AssetsChange
Capital world investors---11.15M
Lynx1 capital management lp546.12K0.14%-10.51M
Darwin global management---10.48M
Boxer capital---3.85M
Foresite capital management vi---2.88M

New Positions

HolderShares% AssetsChangeValue
Sio capital management13.32M4.59%13.32M$27.71M
Walleye capital3.27M0.02%3.27M$6.80M
Rtw investments, lp3.25M0.06%3.25M$6.76M
Ghisallo capital management3.00M0.12%3.00M$6.24M
Sixth street partners management company2.27M0.00%2.27M$4.73M

Sold Out

HolderChange
Toronto dominion bank-27.00
Capital performance advisors llp-41.00
Dunhill financial-70.00
Federation des caisses desjardins du quebec-100.00
Private wealth management group-140.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026213-0.47%314,931,21470.98%1312.23%130-2.99%5031.58%
Mar 31, 2026119-32.00%82,438,846-49.31%370.70%68-16.05%22-51.11%
Dec 31, 2025108-37.93%99,292,779-38.89%440.81%46-51.06%31-16.22%
Sep 30, 20251668.50%162,395,329-2.90%741.27%8526.87%37-11.90%
Jun 30, 2025160-6.98%183,929,908-6.69%841.00%66-27.47%4714.63%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
American Funds SMALLCAP World A11.15M5.10%-1.12M
State Street® SPDR® S&P® Biotech ETF11.95M3.46%27.45K
Fidelity Select Biotechnology10.35M3.00%800.00K
Vanguard Capital Opportunity Inv9.39M2.72%4.02M
Vanguard Morn Total Stk Mkt Idx Investor8.67M2.51%238.80K
Vanguard Total Stock Mkt Idx Inv8.67M2.51%238.80K
Vanguard MStar Total Stk Mkt Idx Invest8.67M2.51%-
Fidelity Growth Compy Commingled Pl O4.58M2.19%-
Vanguard US Total Market Shares ETF4.34M2.00%-
iShares Russell 2000 ETF6.77M1.96%-120.19K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 21, 2026Douglas Earl Martin SVP, General CounselSell$62.96K
Apr 21, 2026Yoshiyama Annie SVP, FinanceSell$22.14K
Mar 31, 2026Beneski Benjamin Machinas SVP, Chief Technical OfficerSell$7.17K
Mar 16, 2026Beneski Benjamin Machinas SVP, Chief Technical OfficerSell$11.94K
Mar 16, 2026Chang David D President and CEOSell$117.97K

Insider Transactions Trends


DateBuySell
2026 Q2-1
2026 Q1-11
2025 Q4-2
2025 Q2-2
2025 Q1-9

ALLO Ownership FAQ


Who Owns Allogene Therapeutics?

Allogene Therapeutics shareholders are primarily institutional investors at 131.06%, followed by 11.03% insiders and -42.09% retail investors. The average institutional ownership in Allogene Therapeutics's industry, Biotech Stocks , is 49.10%, which Allogene Therapeutics exceeds.

Who owns the most shares of Allogene Therapeutics?

Allogene Therapeutics’s largest shareholders are Blackrock funding, inc. /de (30.15M shares, 12.55%), Blackrock (16.45M shares, 9.72%), and Frazier life sciences management (22.45M shares, 9.34%). Together, they hold 31.61% of Allogene Therapeutics’s total shares outstanding.

Does Blackrock own Allogene Therapeutics?

Yes, BlackRock owns 9.72% of Allogene Therapeutics, totaling 16.45M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 38.32M$. In the last quarter, BlackRock increased its holdings by 6.79M shares, a 70.37% change.

Who is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested?

Pfizer is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.55% of its assets in 22.03M Allogene Therapeutics shares, valued at 46.93M$.

Who is the top mutual fund holder of Allogene Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Allogene Therapeutics shares, with 5.10% of its total shares outstanding invested in 11.15M Allogene Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools